31 May 2019 - 4 Jun 2019
Chicago, Illinois, US
Kymab will be part of the 2019 American Society of Clinical Oncology meeting
The American Society of Oncology Annual Meeting brings together more than 30,000 oncology professionals from around the world to discuss state-of-the-art treatment modalities, new therapies, and ongoing controversies in the field.
Kymab will present details relating to an ongoing first-in-human study of KY1044, a fully human anti-ICOS IgG1 antibody as monotherapy and in combination with atezolizumab in patients with selected advanced malignancies.
The abstract is online at: http://abstracts.asco.org/239/AbstView_239_257225.html.